FDA issued its first warning letter to a dispenser (a medical spa) for violating the Drug Supply Chain Security Act (DSCSA), including failing to source products from authorized trading partners and The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics Compounded "semaglutide" is not FDA approved semaglutide.com